User login

The Florida Society of Ophthalmology

The EyeMDs


News from the FSO

From the American Academy of Ophthalmology

Thursday, November 8, 2012 - 16:15

Live News from the 2012 American Academy of Ophthalmology Meeting

Don’t combine routine corneal cross-linking (CXL) with primary LASIK. This was the contention of Perry S. Binder, MD, during a session at the Refractive Surgery meeting on Friday. “Do not perform corneal cross-linking on primary LASIK cases until we can determine the risk and benefits. If in doubt about a possible high-risk case, consider PRK or a phakic IOL.”

Monday, November 12, 2012 - 16:15

News from the 2012 American Academy of Ophthalmology Meeting

At a media briefing today, Michael X. Repka, MD, MBA, Academy medical director for Governmental Affairs, announced that the Centers for Medicare & Medicaid Services has implemented a physician fee schedule cut effective Jan. 1 of approximately 13.5 percent for cataract surgery. This estimate could change if Congress allows the SGR reduction to take effect.

Tuesday, November 13, 2012 - 16:15

 

More news from the 2012 American Academy of Ophthalmology Meeting

In an overview of recent advances, speakers made it clear that oculoplastics isn’t what it used to be.

Tuesday, November 13, 2012 - 16:15

From the American Academy of Ophthalmology

Tuesday, November 20, 2012 - 16:15

From the American Academy of Ophthalmology

Wednesday, November 28, 2012 - 16:15

From the American Academy of Ophthalmology

Thursday, December 6, 2012 - 16:00

From the American Academy of Ophthalmology

This analysis of data from the Fuchs Endothelial Corneal Dystrophy Genetics Multi-Center Study shows that index cases and affected family members with severe disease (grade 4-6) had a higher prevalence of glaucoma and/or ocular hypertension relative to control subjects or unaffected family members. The authors suggest considering periodic glaucoma assessments when monitoring these patients, particularly those with moderate to advanced disease. Archives of Ophthalmology, November 2012

Wednesday, December 12, 2012 - 16:00

From the American Academy of Ophthalmology

Friday, December 14, 2012 - 16:00

From the American Academy of Ophthalmology

First-year results of two phase 3 studies comparing intravitreal aflibercept, monthly or every two months, with monthly ranibizumab show that aflibercept can potentially decrease the treatment and compliance burden of anti-VEGF treatment. Results show aflibercept dosed monthly or every two months after three initial monthly doses resulted in similar visual and anatomic outcomes as ranibizumab dosed monthly, and with a similar safety and tolerability profile.  Ophthalmology, December 2012

 

Thursday, December 20, 2012 - 15:15

Pages

FSO

About

 
 
 
 
 
 

Why Join?

 
 
 
 
 
 
 
 

Join

 
 
 
 

Contribute

Pay Dues

Upcoming Events

Saturday, November 2, 2019

More details to follow.

TBD
Jackonville, FL